TV-45070: Phase IIb start

This month, Teva will begin a double-blind, placebo-controlled, U.S. Phase IIb trial to evaluate 4% or 8% topical TV-45070 twice daily for 4 weeks in about 330 patients. Teva has exclusive, worldwide ...